Hello, this is Daily Stock, delivering your daily stock market compass.
[이미지: /stdaily/uploads/202609/gen_6abb6268384655.35032099.png]
Key Summary
Hanmi Pharm is drawing keen attention as a core market leader, driven by rapid progress in global clinical trials for its proprietary full-cycle obesity and metabolic disease project (H.O.P and H.M.P.A pipeline).
Its innovative new drug candidate 'HM17321', which goes beyond simple weight loss to preserve and increase muscle mass, solidified global R&D credibility after being out-licensed to Genentech (under the Roche Group) in a deal valued at up to $2.305 billion (approx. KRW 3.2 trillion).
In addition, with domestic approval and commercial launch imminent within the year for 'Efe' (generic name: efpeglenatide)—Korea's first GLP-1 obesity drug candidate—Hanmi Pharm has entered a phase where both its cash cow and new drug pipeline value are undergoing concurrent rerating.
Current Market Context
On September 29, 2026, the South Korean stock market closed with the KOSPI at 6,870.81 and the KOSDAQ at 849.80, continuing through a volatile macroeconomic environment.
The KRW/USD exchange rate stood at 1,357.90, maintaining tension in the FX market. According to Daily Stock's proprietary Fear & Greed Index, the KOSPI sentiment currently sits in "Fear" (35.5), showing contracted investor appetite compared to "Neutral" one week ago (41.7), "Neutral" one month ago (47), and "Fear" three months ago (34.3).
The U.S. NASDAQ market also maintained a defensive tone at an index level of 26,820.38, with NASDAQ Fear & Greed hovering in "Fear" (33.8), following 35.0 in the prior week.
Amid this supply-demand vacuum in large-cap semiconductor and cyclical stocks, Hanmi Pharm continues to demonstrate resilient downside defense and new drug momentum, even under unconfirmed intraday quote status (latest confirmed trading band: KRW 470,000 to KRW 520,000 in late September).
Notably, on September 29, 2026, the National Pension Service (NPS) disclosed that it increased its stake in Hanmi Pharm to 10.04%, confirming steady inflows from long-term institutional capital.
Hanmi Pharm's obesity project, 'H.O.P (Hanmi Obesity Pipeline)', has advanced onto broad clinical tracks centered around six core pipelines.
The lead candidate, efpeglenatide (Efe), confirmed weight reduction (-9.75% to up to -30%) and solid tolerability in Korean Phase 3 clinical trials. It is currently slated for domestic regulatory approval in 2H 2026 through the Ministry of Food and Drug Safety's (MFDS) Global Innovative Products on Fast Track (GIFT) program.
The next-generation triple agonist 'HM15275' (LA-GLP/GIP/GCG) successfully completed patient enrollment for its U.S. Phase 2 trial. Targeting over 25% weight loss while preventing muscle loss, it is on track to secure key data by early 2027.
Furthermore, the CRF2 receptor agonist 'HM17321', which was out-licensed to Genentech last August, completed U.S. Phase 1 trials; Genentech will oversee global development starting from Phase 2, driving a sharp revaluation of the asset.
| Pipeline Name | Target Mechanism & Features | Global Clinical Stage | Key Timeline & Partnership |
|---|---|---|---|
| **Efe (Efpeglenatide)** | Korean-tailored GLP-1 mono-agent | Domestic Phase 3 Completed | Domestic approval and launch expected in 2H 2026 |
| **HM15275** | GLP-1 / GIP / GCG triple agonist | U.S. FDA Phase 2 Ongoing | Target primary endpoint readout in early 2027 |
| **HM17321** | UCN2 analog (CRF2 target, muscle-increasing) | U.S. FDA Phase 1 Ongoing | Out-licensed to Roche Genentech (Total $2.3B, upfront $190M) |
| **HM500197** | Peptide-based myostatin inhibitor | Preclinical & early development | Expansion into combination therapy for muscle quality improvement |
[이미지: /stdaily/uploads/202609/gen_6abb6273d53039.63704790.png]
Financial Analysis
Hanmi Pharm recorded strong consolidated results in 1H 2026, with revenue of KRW 860.2 billion and operating profit of KRW 184.7 billion, up 14.4% and 54.6% year-over-year, respectively.
In particular, 2Q 2026 operating profit reached KRW 131.1 billion (+116.9% YoY), boosted by robust domestic outpatient prescription sales of the dyslipidemia combination drug 'Rosuzet' and partial recognition of upfront payments received from Eli Lilly for sonepeglenatide.
According to securities consensus estimates, Hanmi Pharm's full-year 2026 revenue is expected to reach KRW 1.65 trillion to KRW 1.67 trillion, with annual operating profit estimated at around KRW 290 billion to KRW 300 billion.
If the $190 million (approx. KRW 262.9 billion) non-refundable upfront payment for HM17321 from Roche Genentech is recognized in phases during the second half, cash flows and profitability could scale up further.
The company maintains a distinguished financial structure wherein operating cash flows generated from in-house incrementally modified and combination drugs are organically reinvested into proprietary R&D.
Valuation
Hanmi Pharm is currently trading in the high-KRW 400,000s to low-KRW 500,000s, implying a 2026E P/E of 24–26x and an EV/EBITDA of 12–13x.
This represents a significant valuation discount relative to KOSPI 200 large-cap healthcare peers and global big pharma players (e.g., Eli Lilly and Novo Nordisk trading at forward P/Es of 30–35x).
This discount stems from the fact that Hanmi Pharm's market cap has largely reflected only the operating value of its core outpatient prescription drug business (approx. KRW 3.8 trillion), while the full asset value of its obesity pipeline has yet to be baked in.
Combining brokerage estimates for HM17321's pipeline value (approx. KRW 1.7 trillion) with the potential partnering value of HM15275, the total novel drug pipeline value is estimated at over KRW 4.3 trillion.
Accordingly, major research institutions have set target prices between KRW 650,000 and up to KRW 730,000.
Institutional & Analyst Insights
Major domestic brokerage houses assess that Hanmi Pharm's H.O.P project is not a simple fast follower, but a potential 'game changer in next-generation obesity therapies.'
Roche's decision in late September 2026 to discontinue development of its existing myostatin candidate (emugrovart) from Japan's Chugai Pharmaceutical and prioritize Hanmi Pharm's in-licensed HM17321 highlights the superior profile of Hanmi's molecule.
Samsung Securities and Kiwoom Securities analyzed that the proven platform capabilities validated through HM17321's licensing deal are highly likely to enhance Hanmi's bargaining power in prospective global licensing negotiations for the follow-on triple agonist HM15275.
In terms of institutional and foreign capital flows, there is clear selective buying into Hanmi Pharm as a large-cap healthcare name offering high defensive characteristics amid FX volatility around 1,357 KRW/USD.
In particular, the National Pension Service's stake crossing the 10% threshold indicates institutional focus moving past legacy governance disputes and betting on corporate core fundamentals and R&D fruition.
Risk Factors
Potential shortfalls in clinical data or safety signals during global Phase 1 and Phase 2 trials remain an inherent risk for biotech drug development.
Investors must consider that even though upfront cash has been secured, subsequent milestone payments could be suspended if clinical trials fail to meet expectations.
In the domestic market, key variables affecting short-term performance will be how quickly and effectively the first domestic obesity drug Efe can capture market share and assert pricing power against dominant incumbents like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.
On the macroeconomic front, investors should monitor rollover dynamics in foreign futures and profit-taking in cash equities prompted by delayed rate cuts from the U.S. Federal Reserve and the Bank of Korea, as well as heightened KRW/USD volatility.
Investment Takeaway
Hanmi Pharm stands as one of the few large Korean R&D pharmaceuticals capable of completing organic clinical development using its own operating cash flows.
The current sluggish sentiment—with the KOSPI Fear & Greed Index in "Fear" (35.5)—creates an attractive backdrop for phased accumulation of fundamentally sound, earnings-backed pipeline leaders over speculative bio-thematic names.
In the short term, domestic MFDS approval of the obesity drug 'Efe' in 2H could serve as an immediate share-price catalyst.
Over the medium to long term, the early 2027 U.S. Phase 2 top-line readout for HM15275 and global commercialization milestones for HM17321 via Genentech are expected to serve as primary pillars for enterprise valuation rerating.
[이미지: /stdaily/uploads/202609/gen_6abb627ee0c779.40060493.png]
Investor Checkpoint Q&A
Q1. What is the distinction between H.M.P.A and H.O.P mentioned in the market?
A. Hanmi Pharm's obesity pipeline project is officially branded as 'H.O.P (Hanmi Obesity Pipeline)', representing a strategic portfolio spanning the entire continuum of obesity and metabolic pipeline assets.
Q2. What is the core competitive advantage of HM17321, out-licensed to Genentech?
A. It addresses the critical limitation of traditional GLP-1 therapies—concomitant muscle loss during weight reduction. By selectively targeting the CRF2 receptor, it is a First-in-Class drug candidate designed to reduce body fat while increasing muscle mass.
Q3. What differentiates the domestic obesity candidate 'Efe', aiming for launch within the year?
A. Optimized through Phase 3 trials on Korean patients, it demonstrated reduced adverse events such as nausea/vomiting. Manufactured locally at Hanmi's Pyeongtaek Bio Plant, it is expected to offer reliable domestic supply and clear cost competitiveness over imported global alternatives.
Q4. What is the global development timeline for the triple agonist HM15275?
A. It has completed patient enrollment for U.S. FDA Phase 2 trials. Following a 36-week dosing analysis, the company aims to conclude the trial and secure key data in 1H 2027, targeting commercialization by 2030.
Q5. What should investors consider before entering at current valuations?
A. With a 2026E P/E in the mid-20x range—discounted compared to global big pharma peers—downside rigidity is strong. However, factoring in macro FX volatility and potential foreign outflows, a phased dollar-cost averaging strategy around the KRW 480,000–500,000 range remains prudent.